Moderna touts broader antibody data on updated Covid vaccine as it gears up for fall rollout
As Moderna awaits an FDA decision to kick-start its fall Covid vaccination campaign, the biotech is continuing to beef up its data package.
Moderna reported new clinical trial data Wednesday suggesting that its updated Covid-19 vaccine generates neutralizing antibodies against BA.2.86, or Pirola, a variant that is being monitored. Based on a research assay, the jab led to an 8.7-fold increase in antibodies against this specific variant. BA.2.86 is a highly mutated variant, according to the company, which the CDC has noted “may be more likely to break through existing immunity from previous vaccination or infection.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.